Atea Pharmaceuticals (AVIR) Competitors

$4.15 +0.01 (+0.24%)

Closing price 04:00 PM Eastern

Extended Trading

$4.16 +0.00 (+0.12%)

As of 04:10 PM Eastern

AVIR vs. MBX, PVLA, HRMY, ZYME, and AGIO

Should you buy Atea Pharmaceuticals stock or one of its competitors? MarketBeat compares Atea Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atea Pharmaceuticals include MBX Biosciences (MBX), Palvella Therapeutics (PVLA), Harmony Biosciences (HRMY), Zymeworks (ZYME), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical products" industry.

How does Atea Pharmaceuticals compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

MBX Biosciences is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

MBX Biosciences presently has a consensus target price of $60.22, suggesting a potential upside of 98.16%. Given MBX Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe MBX Biosciences is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 18.1% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MBX Biosciences has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

In the previous week, MBX Biosciences had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 6 mentions for MBX Biosciences and 4 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.79 beat MBX Biosciences' score of 0.40 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences' return on equity of -24.52% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Summary

MBX Biosciences beats Atea Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Palvella Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 20.5% of Palvella Therapeutics shares are owned by company insiders. Comparatively, 18.1% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Palvella Therapeutics presently has a consensus target price of $199.53, indicating a potential upside of 82.72%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Palvella Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Palvella Therapeutics has higher revenue and earnings than Atea Pharmaceuticals. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	36.58	-$41.72M	-$4.17	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

Palvella Therapeutics has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

In the previous week, Palvella Therapeutics had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 6 mentions for Palvella Therapeutics and 4 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.79 beat Palvella Therapeutics' score of -0.43 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palvella Therapeutics' return on equity of -56.87% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Summary

Palvella Therapeutics beats Atea Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Harmony Biosciences?

Atea Pharmaceuticals (NASDAQ:AVIR) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

In the previous week, Atea Pharmaceuticals and Atea Pharmaceuticals both had 4 articles in the media. Atea Pharmaceuticals' average media sentiment score of 0.79 beat Harmony Biosciences' score of 0.74 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harmony Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harmony Biosciences has a net margin of 16.20% compared to Atea Pharmaceuticals' net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Harmony Biosciences	16.20%	17.19%	11.99%

Harmony Biosciences has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Harmony Biosciences	$868.45M	2.03	$158.69M	$2.48	12.27

86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 18.1% of Atea Pharmaceuticals shares are held by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Harmony Biosciences has a consensus price target of $40.89, suggesting a potential upside of 34.33%. Given Harmony Biosciences' higher probable upside, analysts clearly believe Harmony Biosciences is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

Atea Pharmaceuticals has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Summary

Harmony Biosciences beats Atea Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Zymeworks?

Atea Pharmaceuticals (NASDAQ:AVIR) and Zymeworks (NASDAQ:ZYME) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 18.1% of Atea Pharmaceuticals shares are held by insiders. Comparatively, 33.5% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Zymeworks had 9 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 13 mentions for Zymeworks and 4 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.79 beat Zymeworks' score of 0.57 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Atea Pharmaceuticals has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Zymeworks	-126.92%	-37.97%	-25.31%

Zymeworks has higher revenue and earnings than Atea Pharmaceuticals. Zymeworks is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Zymeworks	$105.96M	16.81	-$81.13M	-$1.37	N/A

Atea Pharmaceuticals has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Zymeworks has a consensus target price of $38.00, suggesting a potential upside of 55.74%. Given Zymeworks' stronger consensus rating and higher possible upside, analysts plainly believe Zymeworks is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

Zymeworks beats Atea Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Agios Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

86.7% of Atea Pharmaceuticals shares are held by institutional investors. 18.1% of Atea Pharmaceuticals shares are held by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Agios Pharmaceuticals has a consensus price target of $41.56, suggesting a potential upside of 49.86%. Given Agios Pharmaceuticals' higher possible upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

In the previous week, Agios Pharmaceuticals had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 5 mentions for Agios Pharmaceuticals and 4 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.79 beat Agios Pharmaceuticals' score of 0.23 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agios Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Atea Pharmaceuticals has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -639.84%. Agios Pharmaceuticals' return on equity of -34.11% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%

Atea Pharmaceuticals has higher earnings, but lower revenue than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Agios Pharmaceuticals	$54.03M	30.52	-$412.78M	-$7.25	N/A

Atea Pharmaceuticals has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

Summary

Atea Pharmaceuticals beats Agios Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Atea Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVIR vs. The Competition

Export

Metric	Atea Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$331.31M	$3.25B	$6.25B	$12.23B
Dividend Yield	N/A	2.34%	2.80%	5.27%
P/E Ratio	-1.97	18.52	20.79	25.04
Price / Sales	N/A	270.32	531.21	72.17
Price / Cash	N/A	124.58	43.09	54.25
Price / Book	1.42	6.60	9.81	6.83
Net Income	-$158.35M	$24.18M	$3.55B	$335.69M
7 Day Performance	-24.55%	-3.56%	-2.07%	-2.03%
1 Month Performance	-27.70%	-7.86%	-3.90%	-1.90%
1 Year Performance	47.69%	51.80%	29.39%	27.36%

Atea Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVIR Atea Pharmaceuticals	1.2929 of 5 stars	$4.15 +0.2%	N/A	+51.1%	$331.31M	N/A	N/A	70	Earnings Report
MBX MBX Biosciences	3.0956 of 5 stars	$36.98 -7.7%	$60.22 +62.9%	N/A	$1.76B	N/A	N/A	N/A	Analyst Downgrade
PVLA Palvella Therapeutics	3.1021 of 5 stars	$125.79 +3.0%	$199.53 +58.6%	+376.4%	$1.75B	N/A	N/A	N/A
HRMY Harmony Biosciences	4.753 of 5 stars	$30.15 -0.1%	$40.89 +35.6%	-14.9%	$1.75B	$868.45M	12.16	200
ZYME Zymeworks	3.268 of 5 stars	$23.90 -0.5%	$38.00 +59.0%	N/A	$1.75B	$105.96M	N/A	460	Buyback Announcement

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVIR) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. MBX, PVLA, HRMY, ZYME, and AGIO

How does Atea Pharmaceuticals compare to MBX Biosciences?

Summary

How does Atea Pharmaceuticals compare to Palvella Therapeutics?

Summary

How does Atea Pharmaceuticals compare to Harmony Biosciences?

Summary

How does Atea Pharmaceuticals compare to Zymeworks?

Summary

How does Atea Pharmaceuticals compare to Agios Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. MBX, PVLA, HRMY, ZYME, and AGIO

How does Atea Pharmaceuticals compare to MBX Biosciences?

Which has stronger earnings & valuation, MBX or AVIR?

Do analysts prefer MBX or AVIR?

Do institutionals & insiders have more ownership in MBX or AVIR?

Which has more volatility & risk, MBX or AVIR?

Does the media favor MBX or AVIR?

Is MBX or AVIR more profitable?

Summary

How does Atea Pharmaceuticals compare to Palvella Therapeutics?

Do insiders and institutionals believe in PVLA or AVIR?

Do analysts recommend PVLA or AVIR?

Which has better earnings & valuation, PVLA or AVIR?

Which has more risk and volatility, PVLA or AVIR?

Does the media prefer PVLA or AVIR?

Is PVLA or AVIR more profitable?

Summary

How does Atea Pharmaceuticals compare to Harmony Biosciences?

Does the media refer more to AVIR or HRMY?

Is AVIR or HRMY more profitable?

Which has stronger earnings and valuation, AVIR or HRMY?

Do insiders & institutionals have more ownership in AVIR or HRMY?

Do analysts recommend AVIR or HRMY?

Which has more volatility and risk, AVIR or HRMY?

Summary

How does Atea Pharmaceuticals compare to Zymeworks?

Do institutionals and insiders have more ownership in AVIR or ZYME?

Does the media refer more to AVIR or ZYME?

Is AVIR or ZYME more profitable?

Which has better valuation and earnings, AVIR or ZYME?

Which has more volatility & risk, AVIR or ZYME?

Do analysts recommend AVIR or ZYME?

Summary

How does Atea Pharmaceuticals compare to Agios Pharmaceuticals?

Do institutionals & insiders have more ownership in AVIR or AGIO?

Do analysts rate AVIR or AGIO?

Does the media refer more to AVIR or AGIO?

Is AVIR or AGIO more profitable?

Which has better earnings and valuation, AVIR or AGIO?

Which has more risk & volatility, AVIR or AGIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools